8.24
price up icon3.91%   0.31
after-market Dopo l'orario di chiusura: 8.24
loading

Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie

pulisher
Nov 03, 2024

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Nov 03, 2024
pulisher
Oct 31, 2024

Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Lexeo shares dip on early data with Alzheimer's gene therapy - pharmaphorum

Oct 31, 2024
pulisher
Oct 31, 2024

Lexeo reports positive Alzheimer's drug trial results - Investing.com India

Oct 31, 2024
pulisher
Oct 30, 2024

Lexeo reports positive Alzheimer's drug trial results By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

How now, tau? ‘Newer science’ shines in Lexeo Alzheimer’s data - BioWorld Online

Oct 30, 2024
pulisher
Oct 30, 2024

Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment - MarketWatch

Oct 30, 2024
pulisher
Oct 30, 2024

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to - The Bakersfield Californian

Oct 30, 2024
pulisher
Oct 30, 2024

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan

Oct 30, 2024
pulisher
Oct 29, 2024

Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World

Oct 29, 2024
pulisher
Oct 27, 2024

(LXEO) Investment Analysis - Stock Traders Daily

Oct 27, 2024
pulisher
Oct 27, 2024

Novo Holdings A S Trims Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat

Oct 27, 2024
pulisher
Oct 25, 2024

Lexeo Therapeutics' (LXEO) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat

Oct 25, 2024
pulisher
Oct 22, 2024

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference - The Manila Times

Oct 22, 2024
pulisher
Oct 22, 2024

Lexeo Therapeutics to Present New Interim Data from Phase - GlobeNewswire

Oct 22, 2024
pulisher
Oct 22, 2024

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference - StockTitan

Oct 22, 2024
pulisher
Oct 21, 2024

R. Nolan Townsend - Crain's New York Business

Oct 21, 2024
pulisher
Oct 17, 2024

(LXEO) Proactive Strategies - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 15, 2024

Insider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 5,000 Shares of Stock - MarketBeat

Oct 15, 2024
pulisher
Oct 09, 2024

Lexeo Therapeutics (NASDAQ:LXEO) Files 8-K Disclosing Change in Directors or Principal Officers - MarketBeat

Oct 09, 2024
pulisher
Oct 06, 2024

Long Term Trading Analysis for (LXEO) - Stock Traders Daily

Oct 06, 2024
pulisher
Sep 30, 2024

Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

Novo Holdings A S Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth By Investing.com - Investing.com UK

Sep 30, 2024
pulisher
Sep 18, 2024

Can you now get a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News

Sep 18, 2024
pulisher
Sep 18, 2024

Aurobindo to acquire 49% stake in GLS Pharma for Rs 22.5 crore - The Economic Times

Sep 18, 2024
pulisher
Sep 18, 2024

LXP Industrial Trust (NYSE:LXP) PT Raised to $11.00 at Evercore ISI - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Lexicon Pharmaceuticals President and COO Jeffrey Wade to step down - The Business Journals

Sep 17, 2024
pulisher
Sep 17, 2024

How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle

Sep 17, 2024
pulisher
Sep 17, 2024

Quest Partners LLC Acquires 11,597 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Financial Analysis: Lexaria Bioscience (NASDAQ:LEXX) & Xeris Biopharma (NASDAQ:XERS) - Defense World

Sep 17, 2024
pulisher
Sep 16, 2024

Get in on Lexicon Pharmaceuticals Inc’s (LXRX) buy-in window today! - SETE News

Sep 16, 2024
pulisher
Sep 16, 2024

LXP Industrial Trust price target raised to $11 from $10 at Evercore ISI - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

Investor’s Delight: Lexicon Pharmaceuticals Inc (LXRX) Closes Strong at 1.70, Up 1.80 - The Dwinnex

Sep 16, 2024
pulisher
Sep 15, 2024

Objective long/short (LXEO) Report - Stock Traders Daily

Sep 15, 2024
pulisher
Sep 14, 2024

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus Price Target from Analysts - MarketBeat

Sep 14, 2024
pulisher
Sep 14, 2024

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update - MarketBeat

Sep 14, 2024
pulisher
Sep 14, 2024

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World

Sep 14, 2024
pulisher
Sep 12, 2024

Gene Therapies For Cardiomyopathies Market Growth Anticipated - openPR

Sep 12, 2024
pulisher
Sep 12, 2024

The Globe and Mail - The Globe and Mail

Sep 12, 2024
pulisher
Sep 11, 2024

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares - MarketBeat

Sep 11, 2024
pulisher
Sep 05, 2024

Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Sep 05, 2024
pulisher
Sep 02, 2024

Top investors say Lexeo Therapeutics Inc. (LXEO) ticks everything they need - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

The Lexeo Therapeutics Inc. (LXEO) had a good session last reading, didn’t it? - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expands By 16.9% - MarketBeat

Sep 02, 2024
pulisher
Aug 30, 2024

Trading (LXEO) With Integrated Risk Controls - Stock Traders Daily

Aug 30, 2024
pulisher
Aug 20, 2024

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Average Price Target from Analysts - MarketBeat

Aug 20, 2024
pulisher
Aug 19, 2024

Chardan Capital Comments on Lexeo Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:LXEO) - MarketBeat

Aug 19, 2024
pulisher
Aug 17, 2024

Vanguard Group Inc. Grows Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat

Aug 17, 2024
pulisher
Aug 16, 2024

Stifel maintains 'Buy' on Lexeo stock, confident amid trial progress By Investing.com - Investing.com Canada

Aug 16, 2024
pulisher
Aug 16, 2024

Chardan Capital Weighs in on Lexeo Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:LXEO) - MarketBeat

Aug 16, 2024
pulisher
Aug 16, 2024

Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Reaffirmed by Chardan Capital - Defense World

Aug 16, 2024
pulisher
Aug 15, 2024

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - MarketBeat

Aug 15, 2024
pulisher
Aug 15, 2024

Q3 2024 Earnings Estimate for Lexeo Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:LXEO) - Defense World

Aug 15, 2024
pulisher
Aug 15, 2024

Royal Bank of Canada Reiterates Outperform Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World

Aug 15, 2024
$19.96
price up icon 5.11%
$75.75
price down icon 0.50%
$376.80
price up icon 0.74%
$53.54
price down icon 2.00%
$207.25
price up icon 1.49%
$108.97
price down icon 2.25%
Capitalizzazione:     |  Volume (24 ore):